Beyond Air Inc XAIR

Morningstar Rating
$2.82 −0.11 (3.75%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

XAIR is trading at a LOCK|GC&@S premium.
Price
$2.84
Fair Value
LOCK|mhlthVt
Uncertainty
LOCK|^D >lJt
1-Star Price
LOCK|scmjxV&
5-Star Price
LOCK|r@%mp^
Economic Moat
LOCK|#?j
Capital Allocation
—

News

Trading Information

Previous Close Price
$2.93
Day Range
$2.82–2.99
52-Week Range
$2.38–55.60
Bid/Ask
$2.71 / $2.97
Shares Outstanding
984,407.00
Market Cap
$2.78M
Volume/Avg
18,174 / 216,399

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
0.20
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
Sector
Healthcare
Industry
Medical Devices
Stock Style Box
Small Core
Total Number of Employees
54

Valuation

Metric
XAIR
Price/Earnings (Normalized)
—
Price/Book Value
1.05
Price/Sales
0.20
Price/Cash Flow
—
Price/Earnings
XAIR

Financial Strength

Metric
XAIR
Quick Ratio
1.60
Current Ratio
3.31
Interest Coverage
−6.72
Quick Ratio
XAIR

Profitability

Metric
XAIR
Return on Assets (Normalized)
−83.71%
Return on Equity (Normalized)
−353.27%
Return on Invested Capital (Normalized)
−84.17%
Return on Assets
XAIR

Medical Devices Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Abbott Laboratories
ABT
LOCK|Fb!#lw!LOCK|@&Kp$169B
Medtronic PLC
MDT
LOCK|F&rT%xLOCK|?ffrF$110B
Stryker Corp
SYK
LOCK|^zm#D&lLOCK|WM$106B
Boston Scientific Corp
BSX
LOCK|Z#z<<F@LOCK|%c@#$62B
Edwards Lifesciences Corp
EW
LOCK|GT@L%Z&kLOCK|jLXgw$49B
DexCom Inc
DXCM
LOCK|ZrCPbkHXLOCK|#Wrg@$32B
GE HealthCare Technologies Inc Common Stock
GEHC
LOCK|&^^^%$LOCK|<H@$29B
Koninklijke Philips NV ADR
PHG
LOCK|HgNLOCK|l#$23B
Steris PLC
STE
LOCK|?kgXbH@LOCK|^@?!v$20B
Zimmer Biomet Holdings Inc
ZBH
LOCK|!Y#z%<!LOCK|Yc#$17B

Sponsor Center